Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Clin Drug Investig. 2018 Nov;38(11):1077-1084. doi: 10.1007/s40261-018-0703-8.
Menopur is a highly purified, urine-derived, human menopausal gonadotropin containing both follicle stimulating hormone (FSH) and luteinizing hormone (LH) activity. It is an effective option for controlled ovarian stimulation (COS) in assisted reproductive technology protocols and for ovulation induction (OI) in anovulatory infertility, and is associated with a different endocrine profile from that of recombinant (r) FSH in these settings (in terms of serum levels of FSH, androgens and/or estradiol). When used for COS in women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), Menopur was as good as rFSH in terms of pregnancy rates (despite being associated with a lower oocyte yield) and was found to improve some aspects of embryo quality in the IVF (but not ICSI) setting; using Menopur in combination with highly purified urinary FSH resulted in similar reproductive outcomes as Menopur alone. Data for Menopur in OI are limited, but suggest ovulation rates may be as good as those with rFSH + rLH (in type 1 anovulation) and rFSH (in type 2 anovulation). Moreover, compared with rFSH, Menopur appeared to be associated with a less pronounced follicular response and a lower risk of ovarian overstimulation.
美诺孕是一种高度纯化的、源自尿液的人绝经期促性腺激素，含有卵泡刺激素（FSH）和促黄体生成素（LH）的活性。它是辅助生殖技术方案中控制性卵巢刺激（COS）和排卵诱导（OI）的有效选择，在这些情况下，它与重组（r）FSH 的内分泌谱不同（就血清 FSH、雄激素和/或雌二醇水平而言）。在接受体外受精（IVF）/胞浆内精子注射（ICSI）的女性中进行 COS 时，美诺孕在妊娠率方面与 rFSH 一样好（尽管与较低的卵母细胞产量相关），并被发现改善了 IVF 中的某些胚胎质量方面（但不是 ICSI）；美诺孕与高纯度尿源性 FSH 联合使用可产生与单独使用美诺孕相似的生殖结局。关于美诺孕在 OI 中的数据有限，但提示排卵率可能与 rFSH+rLH（1 型排卵障碍）和 rFSH（2 型排卵障碍）一样好。此外，与 rFSH 相比，美诺孕似乎与卵泡反应不那么明显和卵巢过度刺激的风险较低相关。
